PVLA - Palvella Therapeutics, Inc.

20.07
-3.910   -19.482%

Share volume: 109,331
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$23.98
-3.91
-0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-17.85%
1 Month
-20.23%
3 Months
40.84%
6 Months
56.43%
1 Year
56.43%
2 Year
56.43%
Key data
Stock price
$20.07
P/E Ratio 
N/A
DAY RANGE
$19.60 - $23.18
EPS 
N/A
52 WEEK RANGE
$11.17 - $29.27
52 WEEK CHANGE
$56.43
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-15-2025
BETA 
-1.57
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$108,642
AVERAGE 30 VOLUME 
$103,757
Company detail
CEO: Wes Kaupinen
Region: US
Website: palvellatx.com
Employees: 0
IPO year: 2024
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania.

Recent news
loading